PEPG
PepGen·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
PEPG Profile
Pepgen Inc.
A clinical-stage biotechnology company that developing treatment for severe neuromuscular and neurological diseases
321 Harrison Avenue, Boston, MA 02118
--
PepGen Inc., was incorporated in Delaware, USA on January 25, 2018. The company is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of serious neuromuscular and neurological diseases. They build on more than ten years of research and development to enhance oligonucleotides or build EDO platforms and use cell-penetrating peptides to improve the absorption and activity of conjugated oligonucleotide therapies. The technology was originally developed by researchers at the University of Oxford in collaboration with the UK Research Council for Research and Innovative Medicine. They are using these EDO peptides to produce a range of oligonucleotide therapeutic candidates.
